Query-to-Resolve: How Medical AI Has Fundamentally Changed How Physicians Research

Physician clinical research has undergone a structural transformation — one that five quarters of ZoomRx behavioral tracking data now documents in precise, measurable terms. The change is not a preference shift. It is a mode shift.

The traditional research workflow — scanning medical journals, visiting manufacturer sites, navigating to clinical decision support tools, assembling evidence link by link — has given way to a faster, more direct approach. Physicians now go directly to AI or CDS tools with a specific question and expect an immediate synthesis. ZoomRx calls this the "query-to-resolve" model, and the behavioral data confirms it has arrived at scale.

What the Behavioral Data Shows

Between Q1 2025 and Q1 2026, medical AI platforms grew 491% in time share among ZoomRx's Heme/Onc panel — but grew 686% in visit share. The gap reveals a critical dynamic: physicians visit AI far more often, but each session resolves rapidly. AI is gaining on volume, not duration. Per-visit duration on AI platforms now matches journal visits: roughly 41 seconds each.

Journal visits tell a parallel story. Visit share held steady, but time-per-visit compressed from 78.5 seconds to 41.5 seconds. Physicians still go to journals — but they retrieve information faster, likely because AI has already synthesized the key findings and they are cross-referencing.

The Platform That Owns Clinical Evaluation

Among dedicated medical AI platforms, OpenEvidence has emerged as the dominant tool for Heme/Onc clinical research. It surged from rank #15 in physician research time share (Q1 2025) to rank #2 (Q1 2026), trailing only NCCN. Three in five physician AI users identify it as their primary platform — approximately 2.5 times the rate of ChatGPT.

The attitudinal data explains the behavioral pattern. Most physicians (61%) systematically cross-reference AI outputs with other sources — a "don't trust but verify" workflow engineered in response to recognized inaccuracies. Physicians use AI for its speed and synthesis capability, catch the manageable errors, and keep moving. Two-thirds of frequent users report that AI inaccuracies have never negatively impacted a clinical decision.

Suggested Read: Physician AI Adoption Has Crossed Every Generation. The Data Proves It.

The Implication for Pharma Digital Strategy

As the research workflow has compressed, brand websites have absorbed the displacement. Pharma brand sites lost 57% of time share and 55% of visit share in the same twelve-month window. Per-visit duration dropped to 39.8 seconds — the lowest of any category ZoomRx tracks.

Standard web analytics will not show you this shift clearly. Impression counts remain stable. Click-through rates look normal. What is declining is sustained physician engagement — and that loss is migrating directly to the platforms where query-to-resolve now happens.

Conclusion

ZoomRx Media Tracking was built to surface exactly this kind of behavioral intelligence — capturing the actual digital journey of verified Heme/Oncs across every channel, including Med AI platforms that traditional analytics cannot see. The full white paper details platform-level breakdowns, site-level rank movements, and the strategic implications for pharma marketing and content teams.